Internal Medicine, Endocrinology, Diabetes, & Metabolism · Orland Park, IL
NPI
1740410968
Since 2009
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
16632 South 107th Court
Orland Park, IL, 60467
Phone (708) 460-7990
Groups this clinician bills Medicare through
Medicare paid, 2024
$296K
10,646 services
Medicare patients, 2024
677
Average age 73
Drug cost, 2024
$3.1M
8,825 prescriptions
Company payments, 2025
$1,726
From 24 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Mehul R Vora was code J0897 (injection, denosumab, 1 mg), 2,161 times for 22 patients. In total Mehul R Vora billed 10,646 services in 31 codes, and Medicare paid $296K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-03-16.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0897 Injection, denosumab, 1 mg | Office | 2,161 | 22 | $20.78 | $45K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 1,499 | 624 | $12.79 | $19K |
| 99214 Office E&M - Established | Office | 1,473 | 609 | $97.04 | $143K |
| 83036 Blood Count | Office | 836 | 361 | $9.49 | $7,933 |
| 82962 Clinical Chemistry | Office | 577 | 266 | $3.19 | $1,843 |
| 95251 Test - Miscellaneous | Office | 505 | 184 | $27.43 | $14K |
| 96372 Injection Administration | Office | 216 | 90 | $11.37 | $2,455 |
| J3420 Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | Office | 128 | 65 | $0.98 | $125 |
| 99204 Office E&M - New | Office | 104 | 104 | $128.58 | $13K |
| 99213 Office E&M - Established | Office | 100 | 82 | $66.89 | $6,689 |
| 99232 Hospital E&M - Subsequent | Facility | 89 | 26 | $63.70 | $5,670 |
| 36415 Venipuncture Blood Collection | Office | 46 | 36 | $8.65 | $398 |
| 99222 Hospital E&M - Initial | Facility | 33 | 28 | $106.14 | $3,502 |
| 99442 Telephone Services | Office | 26 | 24 | $70.70 | $1,838 |
| 95249 Test - Miscellaneous | Office | 21 | 21 | $49.36 | $1,037 |
By year: 2022 $235K for 5,800 services; 2023 $259K for 8,074 services; 2024 $296K for 10,646 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 83036 Blood Count | 836 | 361 | $9.49 | $7,933 |
| 82962 Clinical Chemistry | 577 | 266 | $3.19 | $1,843 |
| 36415 Venipuncture Blood Collection | 46 | 36 | $8.65 | $398 |
Medicare prescription drug claims, 2024
In 2024, the drug Mehul R Vora prescribed most often to Medicare patients was Levothyroxine Sodium, with 610 prescriptions and refills. In total Mehul R Vora wrote 8,825 Medicare prescriptions that cost $3.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Levothyroxine Sodium Generic | 610 | 1,699 | 174 | $6,771 |
| Metformin Hcl Er Metformin Hcl | 581 | 1,631 | 192 | $6,029 |
| Ozempic Semaglutide | 461 | 700 | 111 | $659K |
| Atorvastatin Calcium Generic | 413 | 1,192 | 147 | $3,568 |
| Glipizide Generic | 391 | 1,117 | 127 | $5,442 |
| Unithroid Levothyroxine Sodium | 356 | 925 | 96 | $15K |
| Metformin Hcl Generic | 353 | 1,022 | 119 | $2,569 |
| Glipizide Er Glipizide | 285 | 781 | 91 | $3,562 |
| Ultra-Fine Mini Pen Needle Pen Needle, Diabetic | 266 | 710 | 117 | $33K |
| Jardiance Empagliflozin | 261 | 561 | 77 | $313K |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 252 | 608 | 92 | $46K |
| Tresiba Flextouch U-100 Insulin Degludec | 242 | 584 | 93 | $218K |
| Humalog Kwikpen U-100 Insulin Lispro | 210 | 439 | 74 | $70K |
| Rosuvastatin Calcium Generic | 207 | 582 | 78 | $3,132 |
| Synthroid Levothyroxine Sodium | 182 | 488 | 53 | $16K |
Brand drugs: 3,730 claims; generic drugs: 4,393 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Mehul R Vora $1,726 ($1,726 in general payments such as food, travel and fees) from 24 companies. The largest payer was Amgen Inc. with $263.
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. AMGN | 9 | $263 |
| Insulet Corporation PODD | 4 | $175 |
| Corcept Therapeutics CORT | 9 | $154 |
| Xeris Pharmaceuticals, Inc. | 6 | $123 |
| Lilly USA, LLC LLY | 10 | $120 |
| Sequel Med Tech, LLC | 4 | $112 |
| Novo Nordisk Inc NVO | 4 | $110 |
| Radius Health, Inc. | 5 | $105 |
| Madrigal Pharmaceuticals MDGL | 4 | $84.32 |
| Phathom Pharmaceuticals, Inc. PHAT | 1 | $76.59 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.